logo

Onconova Therapeutics, Inc (ONTX)



Trade ONTX now with
  Date
  Headline
5/13/2019 7:38:52 AM Onconova Therapeutics Announces License Agreement With HanX Biopharma To Develop Rigosertib In Greater China
3/26/2019 7:42:10 AM ONCONOVA THERAPEUTICS FY Loss Per Share $4.99 Vs Loss $40.15 Last Year
1/15/2019 5:20:06 PM Onconova Therapeutics Promotes Steven Fruchtman To CEO
1/2/2019 7:34:13 AM Onconova Submits Special Protocol Assessment To FDA For Phase 3 Trial Of Oral Rigosertib In Combination With Azacitidine
12/3/2018 7:47:58 AM Onconova Therapeutics Presents Results From Phase 2 Trial Of Oral Rigosertib In Combination With Azacitidine
11/13/2018 7:13:24 AM Onconova Therapeutics Q3 Loss Per Share $0.94 Vs Loss $10.60 Last Year
11/5/2018 8:36:33 AM Onconova Announces Four Presentations From Rigosertib Clinical Trials In Myelodysplastic Syndromes
10/17/2018 8:36:37 AM Onconova Therapeutics Reports Issuance Of New U.S. Patent For Rigosertib
8/21/2018 8:36:29 AM Onconova Says Pint Pharma GmbH Will Assist In Expanding Access To Clinical Trials Studying Rigosertib
8/14/2018 8:10:44 AM Onconova Therapeutics Q2 Net Loss $4.3 Mln Vs Loss Of $2.6 Mln Last Year
6/21/2018 8:04:56 AM Onconova Therapeutics Announces Promotion Of Steven Fruchtman
5/15/2018 8:38:20 AM Onconova Therapeutics Q1 Loss Attributable To Co $5.09 Mln Or $0.34/Shr Vs Loss $8.34 Mln Or $1.23/Shr Last Year
4/27/2018 6:01:58 AM Onconova Therapeutics Announces Pricing Of $25.0 Mln Upsized Underwritten Public Offering
3/26/2018 8:37:29 AM Onconova Presents Data From Phase 2 Expansion Study Of Oral Rigosertib And Azacitidine
  
 
>